Search Results (129)

Periodontitis is a chronic, multifactorial inflammatory disease characterized by the progressive destruction of the tooth-supporting structures. Conventional therapeutic approaches, including mechanical debridement and systemic antibiotics, often fall short in achieving complete bacterial eradication or tissue regeneration, particularly in deep periodontal pockets. Nanotheranostics—an integrated platform combining diagnostics and therapeutics within a single nanosystem—holds promise in advancing periodontal care through targeted delivery, real-time disease monitoring, and site-specific therapy. This narrative review examines the potential of various nanomaterials for building nanotheranostic systems to overcome current clinical limitations, including non-specific drug delivery, insufficient treatment monitoring, and delayed intervention, and their functionalization and responsiveness to the periodontal microenvironment are discussed. Their application in targeted antimicrobial, anti-inflammatory, and regenerative therapy is discussed in terms of real-time monitoring of disease biomarkers and pathogenic organisms. Although nanoparticle-based therapeutics have been extensively studied in periodontitis, the integration of diagnostic elements remains underdeveloped. This review identifies key translational gaps, evaluates emerging dual-function platforms, and discusses challenges related to biocompatibility, scalability, and regulatory approval. In particular, inorganic nanomaterials exhibit potential for theranostic functions such as antimicrobial activity, biofilm disruption, immunomodulation, tissue regeneration, and biosensing of microbial and inflammatory biomarkers. Finally, we propose future directions to advance nanotheranostic research toward clinical translation. By consolidating the current evidence base, this review advocates for the development of smart, responsive nanotheranostic platforms as a foundation for personalized, minimally invasive, and precision-guided periodontal care. Full article

The integration of nanotheranostics into cancer treatment represents a transformative shift in oncology, combining precision diagnostics with targeted therapeutic interventions. This manuscript explores the advancements in nanotechnology-driven cancer therapies, highlighting the role of engineered nanoparticles, such as liposomes, dendrimers, polymeric micelles, and virus-like particles, in enhancing drug delivery, real-time imaging, and tumor-specific targeting. Additionally, emerging therapies, including immunotherapy, gene editing, and chromophore-assisted light inactivation (CALI), are discussed in the context of personalized medicine. The convergence of these strategies is poised to redefine cancer treatment paradigms, improving therapeutic efficacy while minimizing systemic toxicity. This review outlines the key challenges, current limitations, and future directions in nanotheranostic applications, emphasizing the need for interdisciplinary collaboration to optimize their clinical translation. Full article

Silver sulfide quantum dots (Ag₂S QDs) are promising nanomaterials for biomedical applications due to their near-infrared emission and biocompatibility. In this study, Ag₂S QDs were synthesized using bovine serum albumin (BSA) as a stabilizing and reducing agent to assess their potential in targeted photothermal therapy. The QDs showed an average size of 1.06 ± 0.38 nm by DLS and 4.42 nm by TEM. Conjugation to an anti-PSG1 monoclonal antibody was performed via EDC/Sulfo-NHS chemistry and confirmed by FTIR spectroscopy, a decrease in zeta potential, and a redshift in emission. The conjugate exhibited an average size of 22.82 ± 9.7 nm and a zeta potential of +85.7 mV, indicating high colloidal stability. Fluorescence studies showed that the conjugate emits at 590 nm when excited at 560 nm, whereas the BSA-Ag₂S QDs (non-conjugated) emit at 480 nm upon excitation at 400 nm, reflecting changes in optical properties due to conjugation. Thermal imaging under 808 nm laser irradiation revealed efficient photothermal conversion, with temperature increases up to 13.6 °C at 200 μg/mL and a conversion efficiency of 11.41 ± 0.04%. The conjugate was non-cytotoxic to fibroblasts but induced selective cytotoxicity in HeLa cells after laser exposure, with a selectivity index of 3.0. These findings suggest that Ag₂S-BSA QDs conjugated with anti-PSG1 represent promising candidates for further investigation in cancer nanotheranostics. Full article

The convergence of nanotechnology with nuclear medicine has led to the development of theranostic nanoplatforms that combine targeted imaging and therapy within a single system. This review provides a critical and updated synthesis of the current state of nanoplatform-based theranostics, with a particular focus on their application in oncology. We explore multifunctional nanocarriers that integrate diagnostic radionuclides for SPECT/PET imaging with therapeutic radioisotopes (α-, β-, or Auger emitters), chemotherapeutics, and biological targeting ligands. We highlight advances in nanomaterial engineering—such as hybrid architectures, surface functionalization, and stimuli-responsive designs—that improve tumor targeting, biodistribution, and therapeutic outcomes. Emphasis is placed on translational challenges including pharmacokinetics, toxicity, regulatory pathways, and GMP-compliant manufacturing. The article closes with a forward-looking perspective on how theranostic nanoplatforms could reshape the future of personalized oncology through precision-targeted diagnostics and radiotherapy. Full article

Nanotheranostics combines therapeutic and diagnostic functions within multifunctional nanoparticle platforms to enable precision medicine. This review outlines a comprehensive framework for engineering nanotheranostic systems, focusing on core material composition, surface functionalization, and stimuli-responsive drug delivery. Targeting strategies—from ligand-based recognition to biomimetic interfaces—are examined alongside therapeutic modalities such as chemotherapy, photothermal and photodynamic therapies, gene silencing via RNA interference, and radio sensitization. We discuss advanced imaging techniques (fluorescence imaging FI), magnetic resonance imaging (MRI), positron emission tomography (PET), and photoacoustic imaging for real-time tracking and treatment guidance. Key considerations include physicochemical characterization (e.g., article size, surface charge, and morphology), biocompatibility, in-vitro efficacy, and in-vivo biodistribution. We also address challenges such as rapid biological clearance, tumor heterogeneity, and clinical translation, and propose future directions for developing safe, adaptable, and effective nanotheranostic platforms. This review serves as a roadmap for advancing next-generation nano systems in biomedical applications. Full article

The integration of nanotechnology into drug repurposing strategies is redefining the development landscape for diagnostic, therapeutic, and theranostic agents. In radiopharmacy, nanoplatforms are increasingly being explored to enhance or extend the use of existing radiopharmaceuticals, complementing earlier applications in other biomedical fields. Many of these nanoplatforms evolve into multifunctional systems by incorporating additional imaging modalities (e.g., MRI, fluorescence) or non-radioactive therapies (e.g., photodynamic therapy, chemotherapy). These hybrid constructs often emerge from the reformulation, repositioning, or revival of previously approved or abandoned compounds, generating entities with novel pharmacological, pharmacokinetic, and biodistribution profiles. However, their translational potential faces significant regulatory hurdles. Existing frameworks—typically designed for single-modality drugs or devices—struggle to accommodate the combined complexity of nanoengineering, radioactive components, and integrated functionalities. This review examines how these systems challenge current norms in classification, safety assessment, preclinical modeling, and regulatory coordination. It also addresses emerging concerns around digital adjuncts such as AI-assisted dosimetry and software-based therapy planning. Finally, the article outlines international initiatives aimed at closing regulatory gaps and provides future directions for building harmonized, risk-adapted frameworks that support innovation while ensuring safety and efficacy. Full article

Obesity is a chronic disorder associated with serious comorbidities such as diabetes, cardiovascular disease, and cancer. Conventional pharmacological treatments often suffer from limited efficacy, poor selectivity, and undesirable side effects, highlighting the need for more effective alternatives. Nanomedicine offers a promising approach by overcoming these limitations through targeted drug delivery and enhanced therapeutic precision. This review examines key nanotechnological strategies in obesity management, including targeting white adipose tissue (WAT) and the vascular marker prohibitin, promoting WAT browning, and utilizing photothermal therapy and magnetic hyperthermia as nanotheranostic tools. We discuss major nanomedicine platforms—such as liposomes, nanoemulsions, and polymeric nanoparticles—alongside emerging applications in gene nanotherapy and herbal formulations. Potential toxicity concerns are also addressed. In summary, nanomedicine holds substantial potential to revolutionize obesity treatment through targeted, effective, and multifunctional therapeutic strategies. Full article

Background/Objectives. This manuscript presents an overview of advances in oncological radiotherapy as an effective treatment method for cancerous tumors, focusing on mechanisms of action within metabolite–antimetabolite systems. The urgency of this topic is underscored by the fact that cancer remains one of the leading causes of death worldwide: as of 2022, approximately 20 million new cases were diagnosed globally, accounting for about 0.25% of the total population. Given prognostic models predicting a steady increase in cancer incidence to 35 million cases by 2050, there is an urgent need for the latest developments in physics, chemistry, molecular biology, pharmacy, and strict adherence to oncological vigilance. The purpose of this work is to demonstrate the relationship between the nature and mechanisms of past diagnostic and therapeutic oncology approaches, their current improvements, and future prospects. Particular emphasis is placed on isotope technologies in the production of therapeutic nuclides, focusing on the mechanisms of formation of simple and complex theranostic compounds and their classification according to target specificity. Methods. The methodology involved searching, selecting, and analyzing information from PubMed, Scopus, and Web of Science databases, as well as from available official online sources over the past 20 years. The search was structured around the structure–mechanism–effect relationship of active pharmaceutical ingredients (APIs). The manuscript, including graphic materials, was prepared using a narrative synthesis method. Results. The results present a sequential analysis of materials related to isotope technology, particularly nucleus stability and instability. An explanation of theranostic principles enabled a detailed description of the action mechanisms of radiopharmaceuticals on various receptors within the metabolite–antimetabolite system using specific drug models. Attention is also given to radioactive nanotheranostics, exemplified by the mechanisms of action of radioactive nanoparticles such as Tc-99m, AuNPs, wwAgNPs, FeNPs, and others. Conclusions. Radiotheranostics, which combines the diagnostic properties of unstable nuclei with therapeutic effects, serves as an effective adjunctive and/or independent method for treating cancer patients. Despite the emergence of resistance to both chemotherapy and radiotherapy, existing nuclide resources provide protection against subsequent tumor metastasis. However, given the unfavorable cancer incidence prognosis over the next 25 years, the development of “preventive” drugs is recommended. Progress in this area will be facilitated by modern medical knowledge and a deeper understanding of ligand–receptor interactions to trigger apoptosis in rapidly proliferating cells. Full article

This narrative review explores the integration of theranostics and artificial intelligence (AI) in neuro-oncology, addressing the urgent need for improved diagnostic and treatment strategies for brain tumors, including gliomas, meningiomas, and pediatric central nervous system neoplasms. A comprehensive literature search was conducted through PubMed, Scopus, and Embase for articles published between January 2020 and May 2025, focusing on recent clinical and preclinical advancements in personalized neuro-oncology. The review synthesizes evidence on novel theranostic agents—such as Lu-177-based radiopharmaceuticals, CXCR4-targeted PET tracers, and multifunctional nanoparticles—and highlights the role of AI in enhancing tumor detection, segmentation, and treatment planning through advanced imaging analysis, radiogenomics, and predictive modeling. Key findings include the emergence of nanotheranostics for targeted drug delivery and real-time monitoring, the application of AI-driven algorithms for improved image interpretation and therapy guidance, and the identification of current limitations such as data standardization, regulatory challenges, and limited multicenter validation. The review concludes that the convergence of AI and theranostic technologies holds significant promise for advancing precision medicine in neuro-oncology, but emphasizes the need for collaborative, multidisciplinary research to overcome existing barriers and enable widespread clinical adoption. Full article

Brain cancer is a heterogeneous collection of malignant neoplasms, such as glioblastoma multiforme (GBM), astrocytomas and medulloblastomas, with high morbidity and mortality. Its treatment is complicated by the tumor’s site, infiltrative growth mode and selective permeability of the blood–brain barrier (BBB). During tumor formation, the BBB dynamically remodels into the blood–brain tumor barrier (BBTB), disrupting homeostasis and preventing drug delivery. Furthermore, the TME (Tumor Micro Environment) supports drug resistance, immune evasion and treatment failure. This review points out the ways in which nanomedicine overcomes these obstacles with custom-designed delivery systems, sophisticated diagnostics and personalized therapies. Traditional treatments fail through a lack of BBB penetration, non-specific cytotoxicity and swift tumor adaptation. Nanomedicine provides greater drug solubility, protection against enzymatic degradation, target drug delivery and control over the release. Nanotheranostics’ confluence of therapeutic and diagnostic modalities allows for dynamic adjustment and real-time monitoring. Nanotechnology has paved the way for the initiation of a new era in precision neuro-oncology. Transcending the limitations of conventional therapy protocols, nanomedicine promises to deliver better outcomes by way of enhanced targeting, BBB penetration and real-time monitoring. Multidisciplinary collaboration, regulatory advancements and patient-centered therapy protocols customized to the individual patient’s tumor biology will be necessary to facilitate translation success in the future. Full article

Electromagnetic wave (EMW) absorption materials are crucial for a wide range of applications, yet most existing materials suffer from complex fabrication and narrow absorption bands, particularly under harsh environmental conditions. In this study, we introduce a broadband metamaterial absorber based on Ti₃C₂O₂ MXene, a novel two-dimensional material that uniquely combines high electrical and metallic conductivity with hydrophilicity, biocompatibility, and an extensive surface area. Through advanced finite-difference time-domain (FDTD) simulations, the proposed absorber achieves over 95% absorption from 0.3 µm to 18 µm. Additionally, other MXene variants, including Ti₃C₂F₂ and Ti₃C₂(OH)₂, demonstrate robust absorption above 85%. This absorber not only outperforms previously reported structures in terms of efficiency and spectral coverage but also opens avenues for integration into applications such as infrared sensing, energy harvesting, wearable electronics, and Internet of Things (IoT) systems. Full article

Pharmacoscintigraphy has emerged as an essential tool in the research and development of nanomedicines, particularly in the field of nanotheranostics. By enabling the real-time, non-invasive tracking of their biodistribution, pharmacokinetics, and therapeutic efficacy, these imaging techniques provide invaluable insights that drive the optimization of nanomedicine formulations. The integration of gamma scintigraphy, SPECT, and PET imaging has significantly enhanced our understanding of nanocarrier behavior, supporting their clinical translation by ensuring precise targeting, minimizing off-target effects, and improving therapeutic outcomes. Future advancements in hybrid imaging modalities, novel radionuclide tracers, and personalized imaging-guided therapies will further expand the impact of pharmacoscintigraphy in nanomedicine. Additionally, the increasing recognition of imaging-based validation in regulatory approval processes underscores the growing importance of these techniques in drug development. As nanotheranostics continues to evolve, radionuclide imaging will remain a pivotal component in their preclinical and clinical evaluation, facilitating safer and more effective precision medicine approaches. Full article

Nanotheranostics—where nanoscale materials serve both diagnostic and therapeutic functions—are rapidly transforming gene therapy by tackling critical delivery challenges. This review explores the design and engineering of various nanoparticle systems (lipid-based, polymeric, inorganic, and hybrid) to enhance stability, targeting, and endosomal escape of genetic payloads. We discuss how real-time imaging capabilities integrated into these platforms enable precise localization and controlled release of genes, improving treatment efficacy while reducing off-target effects. Key strategies to overcome delivery barriers (such as proton sponge effect and photothermal disruption) and to achieve nuclear localization are highlighted, along with recent advances in stimuli-responsive systems that facilitate spatiotemporal control of gene expression. Clinical trials and preclinical studies demonstrate the expanding role of nanotheranostics in managing cancer, inherited disorders, and cardiovascular and neurological diseases. We further address regulatory and manufacturing hurdles that must be overcome for the widespread clinical adoption of nanoparticle-based gene therapies. By synthesizing recent progress and ongoing challenges, this review underscores the transformative potential of nanotheranostics for effective, targeted, and image-guided gene delivery. Full article

Photodynamic therapy (PDT) and photothermal therapy (PTT) are considered to be one of the most effective methods for treating cancer due to their noninvasive nature, high effectiveness, and fewer side effects compared to standard therapeutic modalities for cancer. However, conventional always-on types of PDT and PTT agents have basic drawbacks in their in vivo applications, which include the unwanted generation of strong fluorescence signals and phototoxicity in normal tissues, including blood vessels, when exposed to light, resulting in poor imaging contrast and unwanted phototoxicity. Here, we propose indocyanine green-loaded quenched nanoliposomes (Q-ICG-NLs) as an activatable nanotheranostics. Q-ICG-NLs showed significant quenching in near-infrared fluorescence emission and singlet oxygen generation upon light irradiation. The photothermal effect of Q-ICG-NLs was 1.3 times greater than free indocyanine green. Its fluorescence and singlet oxygen generation were largely restored when taken up into cancer cells, enabling the selective detection and phototherapy of cancer cells. These results suggest that Q-ICG-NLs can be effectively used for selective near-infrared fluorescence imaging and the subsequent image-guided PDT and PTT of cancers. Full article